Clinical Trial Update: SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study of intravitreal VP-001 in PRPF31 mutation-associated retinal dystrophy (RP11) has completed; no detailed results are provided in the update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinal Dystrophy
• Retinitis Pigmentosa
• Rp11-associated Retinitis Pigmentosa

Drugs mentioned

• VP-001

Snippet

Sponsor: PYC Therapeutics | Conditions: Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy | Phase 1 | Status: COMPLETED